Chloroquine and hydroxychloroquine: Immunomodulatory effects in autoimmune diseases.

Abstract

Chloroquine (CQ) and hydroxychloroquine (HCQ), originally developed as antimalarial drugs, have found a new purpose in treating various autoimmune diseases due to their immunomodulatory properties. These drugs work through multiple mechanisms, including inhibiting Toll-like receptor signaling, suppressing antigen presentation, and modulating autophagy. This review article provides a comprehensive analysis of the immunomodulatory effects of CQ and HCQ in several autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and others. We delve into the intricate mechanisms of action, highlighting the key immune cells involved and discussing the clinical implications of these drugs in managing autoimmune conditions. Our review covers the latest research and clinical trials, offering a comprehensive understanding of the therapeutic potential of CQ and HCQ in autoimmune diseases. We also discuss the challenges and controversies surrounding the use of these drugs, such as their long-term side effects and the need for personalized treatment approaches. By synthesizing current knowledge and identifying areas for future research, this review aims to provide a valuable resource for healthcare professionals and researchers involved in the management of autoimmune diseases.